Oragenics, Inc

📍 Tampa, United States👥 17 employees💰 Last funded 2021
Biotechnology🌐 oragenics.com
Website LinkedIn
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. For more information about Oragenics, please visit www.oragenics.com.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Oragenics, Inc?
Oragenics, Inc has 1 investors on record on gritt.io.
When did Oragenics, Inc last raise funding?
The most recent investment in Oragenics, Inc recorded on gritt.io was in 2021.
What industry is Oragenics, Inc in?
Oragenics, Inc operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Oragenics, Inc based?
Oragenics, Inc is headquartered in Tampa, United States.